Legacy Effects of PCSK9 Inhibitors on Lipid-Rich Vulnerable Coronary Plaque

Legacy Effects of PCSK9 Inhibitors on Lipid-Rich Vulnerable Coronary Plaque - Legacy Effects of PCSK9 Inhibitors

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041925

Enrollment

Registered

2020-09-28

Start date

2017-05-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute coronary syndrome

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: This study included patients with a history of acute coronary syndrome and more than or equal to 50% coronary stenosis, who were administered PCSK9i due to LDL-C levels more than or equal to 70 mg/dl despite the administration of optimized statin therapy

Exclusion criteria

Exclusion criteria: A pregnancy or inability to provide written informed consent, Participants had already had anti-PCSK9 antibody on admission

Design outcomes

Primary

Measure	Time frame
The maxLCBI4mm were assessed at baseline, 9 months after PCSK9i, and after cessation of PCSK9i (24 months)	—

Secondary

Measure	Time frame
The maxLCBI4mm,laque burden measured by IVUS, FFR, and low-density lipoprotein cholesterol (LDL-C) were assessed at baseline, 9 months after PCSK9i, and after cessation of PCSK9i (24 months)	—

Countries

Japan

Contacts

Public ContactHiroyuki Omori

Gifu Heart Center Department of Cardiovascular Medicine

omori@heart-center.or.jp058-277-2277

Outcome results